Robert W. Baird analyst Michael Polark maintained a Buy rating on LivaNova (NASDAQ:LIVN) PLC on Tuesday, setting a price target of $100, which is approximately 19.80% above the present share price of $83.47.
Polark expects LivaNova PLC to post earnings per share (EPS) of -$0.61 for the second quarter of 2021.
The current consensus among 6 TipRanks analysts is for a Moderate Buy rating of shares in LivaNova, with an average price target of $93.6.
The analysts price targets range from a high of $100 to a low of $84.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $247.6 million and a net profit of $4.38 million. The company's market cap is $4.08 billion.
According to TipRanks.com, Robert W. Baird analyst Michael Polark is currently ranked with 2 stars on a 0-5 stars ranking scale, with an average return of 2.1% and a 40.00% success rate.
LivaNova Plc is a global medical technology company, which engages in the development and delivery of important therapeutic solutions for the benefit of patients, healthcare professionals and healthcare systems. It operates through the following segments: Cardiovascular, Neuromodulation, and Others. The Cardiovascular segment develops, produces, and sells cardiopulmonary products, heart valves, and advanced circulatory support products. The Neuromodulation segment designs and markets NM-based medical devices for the treatment of epilepsy, depression, and obstructive sleep apnea. The Other segment consists of company's shared service expenses for finance, legal, human resources, information technology, and new ventures. Its products include VNS therapy system. oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, and cannulae. The company was founded on February 20, 2015 and is headquartered in London, the United Kingdom.